ONKURE THERAPEUTICS, INC. Operating Cash Flow
ONKURE THERAPEUTICS, INC. (OKUR) reported Operating Cash Flow of -$23.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-04
- ONKURE THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$10.35M.
- ONKURE THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$12.94M.
- ONKURE THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$11.51M.
- ONKURE THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$13.04M.
- ONKURE THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$51.83M.
- ONKURE THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$51.12M.
- ONKURE THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$34.55M.
- ONKURE THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$47.36M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$10.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$23.29M 10-Q · filed 2026-08-04 | -$34.80M derived: sum of 3 quarters · filed 2026-08-04 | -$47.84M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | -$12.94M 10-Q · filed 2026-05-05 | -$24.45M derived: sum of 2 quarters · filed 2026-05-05 | -$37.49M derived: sum of 3 quarters · filed 2026-05-05 | -$50.76M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | -$11.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$24.55M derived: sum of 2 quarters · filed 2026-03-12 | -$37.82M derived: sum of 3 quarters · filed 2026-08-04 | -$51.83M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | -$13.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$26.31M derived: sum of 2 quarters · filed 2026-08-04 | -$40.32M 10-Q · filed 2025-11-06 | -$63.67M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | -$13.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$27.28M 10-Q · filed 2026-08-04 | -$50.63M derived: sum of 3 quarters · filed 2026-08-04 | -$61.29M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | -$14.01M 10-Q · filed 2026-05-05 | -$37.36M derived: sum of 2 quarters · filed 2026-05-05 | -$48.02M derived: sum of 3 quarters · filed 2026-05-05 | -$54.49M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | -$23.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$34.02M derived: sum of 2 quarters · filed 2026-03-12 | -$40.49M derived: sum of 3 quarters · filed 2026-03-12 | -$51.12M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | -$10.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$17.13M derived: sum of 2 quarters · filed 2025-11-06 | -$27.76M 10-Q · filed 2025-11-06 | -$30.10M 10-Q · filed 2024-11-07 | -$18.38M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | -$6.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$17.10M 10-Q · filed 2025-08-12 | -$27.82M 10-Q · filed 2024-08-13 | -$7.72M derived: sum of 3 quarters · filed 2025-08-12 | -$26.49M derived: sum of 4 quarters · filed 2025-08-12 | |||
| 2024-03-31 | -$10.63M 10-Q · filed 2025-05-06 | -$21.01M 10-Q · filed 2024-05-07 | -$1.25M derived: sum of 2 quarters · filed 2025-05-06 | -$20.01M derived: sum of 3 quarters · filed 2025-05-06 | -$36.13M derived: sum of 4 quarters · filed 2025-05-06 | |||
| 2023-12-31 | $9.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$9.38M derived: sum of 2 quarters · filed 2025-03-10 | -$25.50M derived: sum of 3 quarters · filed 2025-03-10 | -$34.55M 10-K · filed 2025-03-10 | -$63.68M 10-K · filed 2024-03-28 | |||
| 2023-09-30 | -$18.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$34.88M derived: sum of 2 quarters · filed 2024-11-07 | -$43.93M 10-Q · filed 2024-11-07 | -$59.54M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | -$16.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$25.16M 10-Q · filed 2024-08-13 | -$40.77M derived: sum of 3 quarters · filed 2024-08-13 | -$51.57M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | -$9.05M 10-Q · filed 2024-05-07 | -$24.66M derived: sum of 2 quarters · filed 2024-05-07 | -$35.45M derived: sum of 3 quarters · filed 2024-05-07 | -$47.41M derived: sum of 4 quarters · filed 2024-05-07 | ||||
| 2022-12-31 | -$15.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$26.41M derived: sum of 2 quarters · filed 2024-03-28 | -$38.36M derived: sum of 3 quarters · filed 2024-03-28 | -$47.36M 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | -$10.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$22.75M derived: sum of 2 quarters · filed 2023-11-13 | -$31.75M 10-Q · filed 2023-11-13 | -$41.77M derived: sum of 4 quarters · filed 2023-11-13 | ||||
| 2022-06-30 | -$11.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$20.95M 10-Q · filed 2023-08-10 | -$30.98M derived: sum of 3 quarters · filed 2023-08-10 | -$40.65M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | -$9.00M 10-Q · filed 2023-05-11 | -$19.02M derived: sum of 2 quarters · filed 2023-05-11 | -$28.69M derived: sum of 3 quarters · filed 2023-05-11 | -$38.39M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | -$10.02M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$19.69M derived: sum of 2 quarters · filed 2023-03-27 | -$29.39M derived: sum of 3 quarters · filed 2023-03-27 | -$37.98M 10-K · filed 2023-03-27 | ||||
| 2021-09-30 | -$9.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$19.37M derived: sum of 2 quarters · filed 2022-11-08 | -$27.96M 10-Q · filed 2022-11-08 | -$33.37M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | -$9.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$18.29M 10-Q · filed 2022-08-09 | -$23.70M derived: sum of 3 quarters · filed 2022-08-09 | -$29.44M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | -$8.59M 10-Q · filed 2022-05-10 | -$14.00M derived: sum of 2 quarters · filed 2022-05-10 | -$19.74M derived: sum of 3 quarters · filed 2022-05-10 | -$22.68M derived: sum of 4 quarters · filed 2022-05-10 | ||||
| 2020-12-31 | -$5.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | -$11.15M derived: sum of 2 quarters · filed 2022-03-23 | -$14.09M derived: sum of 3 quarters · filed 2022-03-23 | -$18.54M 10-K · filed 2022-03-23 | ||||
| 2020-09-30 | -$5.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$8.68M derived: sum of 2 quarters · filed 2021-11-12 | -$13.13M 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | -$2.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$7.38M 10-Q · filed 2021-08-11 | ||||||
| 2020-03-31 | -$4.45M 10-Q · filed 2021-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |